Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti

MT NewswiresApr 18 19:57

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireMar 27 21:08

Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of

GlobeNewswireMar 19 19:00

Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation

Seeking AlphaMar 8 00:29

Oregon House Passes Bill to End Hard Drug Decriminalization

There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.

Seeking AlphaMar 1 19:42

Press Release: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO

Dow JonesFeb 27 05:05